

Stein Bergan

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/3927426/stein-bergan-publications-by-year.pdf>

Version: 2024-04-20

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

57
papers

1,066
citations

18
h-index

31
g-index

61
ext. papers

1,395
ext. citations

3.2
avg, IF

4
L-index

#	Paper	IF	Citations
57	Effect of atorvastatin on muscle symptoms in coronary heart disease patients with self-perceived statin muscle side effects: a randomized, double-blinded crossover trial. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2021 , 7, 507-516	6.4	6
56	Therapeutic Drug Monitoring in the Era of Precision Medicine: Achievements, Gaps, and Perspectives-An Interview in Honor of Professor Charles Pippenger. <i>Therapeutic Drug Monitoring</i> , 2021 , 43, 719-727	3.2	1
55	Personalized Therapy for Mycophenolate: Consensus Report by the International Association of Therapeutic Drug Monitoring and Clinical Toxicology. <i>Therapeutic Drug Monitoring</i> , 2021 , 43, 150-200	3.2	17
54	Tacrolimus Measured in Capillary Volumetric Microsamples in Pediatric Patients-A Cross-Validation Study. <i>Therapeutic Drug Monitoring</i> , 2021 , 43, 371-375	3.2	3
53	Fast and reliable quantification of busulfan in blood plasma using two-channel liquid chromatography tandem mass spectrometry: Validation of assay performance in the presence of drug formulation excipients. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2021 , 203, 114216	3.5	1
52	In vitro assessments predict that CYP3A4 contributes to a greater extent than CYP3A5 to prednisolone clearance. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2021 , 129, 427-436	3.1	1
51	Pharmacodynamic assessment of mycophenolic acid in resting and activated target cell population during the first year after renal transplantation. <i>British Journal of Clinical Pharmacology</i> , 2020 , 86, 1100-1112	3.8	4
50	Severe Mycophenolate Intoxication in a Solid Organ Transplant Recipient-No Intervention Actually Needed. <i>Transplantation Direct</i> , 2020 , 6, e609	2.3	
49	Pharmacologic Treatment of Transplant Recipients Infected With SARS-CoV-2: Considerations Regarding Therapeutic Drug Monitoring and Drug-Drug Interactions. <i>Therapeutic Drug Monitoring</i> , 2020 , 42, 360-368	3.2	25
48	Cardiovascular remodeling in living kidney donors with reduced glomerular filtration rate: rationale and design of the CENS study. <i>Blood Pressure</i> , 2020 , 29, 123-134	1.7	1
47	Measured GFR by Utilizing Population Pharmacokinetic Methods to Determine Iohexol Clearance. <i>Kidney International Reports</i> , 2020 , 5, 189-198	4.1	7
46	Tacrolimus Area Under the Concentration Versus Time Curve Monitoring, Using Home-Based Volumetric Absorptive Capillary Microsampling. <i>Therapeutic Drug Monitoring</i> , 2020 , 42, 407-414	3.2	9
45	Measuring Intracellular Concentrations of Calcineurin Inhibitors: Expert Consensus from the International Association of Therapeutic Drug Monitoring and Clinical Toxicology Expert Panel. <i>Therapeutic Drug Monitoring</i> , 2020 , 42, 665-670	3.2	6
44	Fasting Status and Circadian Variation Must be Considered When Performing AUC-based Therapeutic Drug Monitoring of Tacrolimus in Renal Transplant Recipients. <i>Clinical and Translational Science</i> , 2020 , 13, 1327-1335	4.9	4
43	A novel direct method to determine adherence to atorvastatin therapy in patients with coronary heart disease. <i>British Journal of Clinical Pharmacology</i> , 2019 , 85, 2878-2885	3.8	5
42	A Method for Direct Monitoring of Atorvastatin Adherence in Cardiovascular Disease Prevention: Quantification of the Total Exposure to Parent Drug and Major Metabolites Using 2-Channel Chromatography and Tandem Mass Spectrometry. <i>Therapeutic Drug Monitoring</i> , 2019 , 41, 19-28	3.2	8
41	Statin-associated muscle symptoms in coronary patients: design of a randomized study. <i>Scandinavian Cardiovascular Journal</i> , 2019 , 53, 162-168	2	4

40	A Fully Automated Method for the Determination of Serum Belatacept and Its Application in a Pharmacokinetic Investigation in Renal Transplant Recipients. <i>Therapeutic Drug Monitoring</i> , 2019 , 41, 11-18	3.2	6
39	Therapeutic Drug Monitoring of Tacrolimus-Personalized Therapy: Second Consensus Report. <i>Therapeutic Drug Monitoring</i> , 2019 , 41, 261-307	3.2	163
38	Effects of marine n-3 fatty acid supplementation in renal transplantation: A randomized controlled trial. <i>American Journal of Transplantation</i> , 2019 , 19, 790-800	8.7	8
37	Estimated glomerular filtration rate in stable older kidney transplant recipients-are present algorithms valid? A national cross-sectional cohort study. <i>Transplant International</i> , 2018 , 31, 629-638	3	4
36	The AuthorsSReply. <i>Transplantation</i> , 2018 , 102, e43-e44	1.8	
35	The CYP3A biomarker 4hydroxycholesterol does not improve tacrolimus dose predictions early after kidney transplantation. <i>British Journal of Clinical Pharmacology</i> , 2017 , 83, 1457-1465	3.8	15
34	High Tacrolimus Clearance Is a Risk Factor for Acute Rejection in the Early Phase After Renal Transplantation. <i>Transplantation</i> , 2017 , 101, e273-e279	1.8	27
33	Response to: Response to: Bodyweight-adjustments introduce significant correlations between CYP3A metrics and tacrolimus clearances <i>British Journal of Clinical Pharmacology</i> , 2017 , 83, 1357-1358	3.8	1
32	Bodyweight-adjustments introduce significant correlations between CYP3A metrics and tacrolimus clearance. <i>British Journal of Clinical Pharmacology</i> , 2017 , 83, 1350-1352	3.8	5
31	NFAT-regulated cytokine gene expression during tacrolimus therapy early after renal transplantation. <i>British Journal of Clinical Pharmacology</i> , 2017 , 83, 2494-2502	3.8	18
30	Estimating Glomerular Filtration Rate in Kidney Transplant Recipients: Comparing a Novel Equation With Commonly Used Equations in this Population. <i>Transplantation Direct</i> , 2017 , 3, e332	2.3	12
29	Drug target molecules to guide immunosuppression. <i>Clinical Biochemistry</i> , 2016 , 49, 411-8	3.5	8
28	Pharmacology Portal: An Open Database for Clinical Pharmacologic Laboratory Services. <i>Clinical Therapeutics</i> , 2016 , 38, 222-6	3.5	3
27	Treatment with Tacrolimus and Sirolimus Reveals No Additional Adverse Effects on Human Islets In Vitro Compared to Each Drug Alone but They Are Reduced by Adding Glucocorticoids. <i>Journal of Diabetes Research</i> , 2016 , 2016, 4196460	3.9	3
26	Prediction of Fat-Free Mass in Kidney Transplant Recipients. <i>Therapeutic Drug Monitoring</i> , 2016 , 38, 439-46	3.6	3
25	Low-target tacrolimus in de novo standard risk renal transplant recipients: A single-centre experience. <i>Nephrology</i> , 2016 , 21, 821-7	2.2	5
24	Improved Tacrolimus Target Concentration Achievement Using Computerized Dosing in Renal Transplant Recipients--A Prospective, Randomized Study. <i>Transplantation</i> , 2015 , 99, 2158-66	1.8	60
23	Intracellular sirolimus concentration is reduced by tacrolimus in human pancreatic islets in vitro. <i>Transplant International</i> , 2015 , 28, 1152-61	3	6

22	Glomerular filtration rate measured by iohexol clearance: A comparison of venous samples and capillary blood spots. <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> , 2015 , 75, 710-6	2	8
21	Improved prediction of tacrolimus concentrations early after kidney transplantation using theory-based pharmacokinetic modelling. <i>British Journal of Clinical Pharmacology</i> , 2014 , 78, 509-23	3.8	58
20	Pharmacogenetically based dosing of thiopurines in childhood acute lymphoblastic leukemia: influence on cure rates and risk of second cancer. <i>Pediatric Blood and Cancer</i> , 2014 , 61, 797-802	3	21
19	A taste of individualized medicine: physicians' reactions to automated genetic interpretations. <i>Journal of the American Medical Informatics Association: JAMIA</i> , 2014 , 21, e143-6	8.6	9
18	Importance of hematocrit for a tacrolimus target concentration strategy. <i>European Journal of Clinical Pharmacology</i> , 2014 , 70, 65-77	2.8	72
17	Determination of cyclosporine, tacrolimus, sirolimus and everolimus by liquid chromatography coupled to electrospray ionization and tandem mass spectrometry: assessment of matrix effects and assay performance. <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> , 2010 , 70, 583-91	2	21
16	Determination of digoxin and digitoxin in whole blood. <i>Journal of Analytical Toxicology</i> , 2009 , 33, 372-8	2.9	22
15	Cyclosporine C2 levels have impact on incidence of rejection in de novo lung but not heart transplant recipients: the NOCTURNE study. <i>Journal of Heart and Lung Transplantation</i> , 2009 , 28, 919-26	5.8	8
14	Reduced elimination of cyclosporine A in elderly (>65 years) kidney transplant recipients. <i>Transplantation</i> , 2008 , 86, 1379-83	1.8	40
13	Oral anticoagulation with warfarin is significantly influenced by steroids and CYP2C9 polymorphisms in children with cancer. <i>Pediatric Blood and Cancer</i> , 2008 , 50, 710-3	3	14
12	Determination of inosine monophosphate dehydrogenase activity in human CD4+ cells isolated from whole blood during mycophenolic acid therapy. <i>Therapeutic Drug Monitoring</i> , 2006 , 28, 608-13	3.2	23
11	Mycophenolic acid clinical pharmacokinetics influenced by a cyclosporine C2 based immunosuppressive regimen in renal allograft recipients. <i>Transplant International</i> , 2006 , 19, 44-53	3	2
10	Automated determination of free mycophenolic acid and its glucuronide in plasma from renal allograft recipients. <i>Therapeutic Drug Monitoring</i> , 2003 , 25, 407-14	3.2	35
9	TDM: report concentration, C _{ss} , rather than area under the curve, AUC. <i>Therapeutic Drug Monitoring</i> , 2003 , 25, 743	3.2	2
8	Pharmacokinetics of diltiazem and its metabolites in relation to CYP2D6 genotype. <i>Clinical Pharmacology and Therapeutics</i> , 2002 , 72, 333-42	6.1	39
7	Bilateral pharmacokinetic interaction between cyclosporine A and atorvastatin in renal transplant recipients. <i>American Journal of Transplantation</i> , 2001 , 1, 382-6	8.7	111
6	Monitored high-dose azathioprine treatment reduces acute rejection episodes after renal transplantation. <i>Transplantation</i> , 1998 , 66, 334-9	1.8	45
5	Optimisation of azathioprine immunosuppression after organ transplantation by pharmacological measurements. <i>BioDrugs</i> , 1997 , 8, 446-56	7.9	11

4	Patterns of azathioprine metabolites in neutrophils, lymphocytes, reticulocytes, and erythrocytes: relevance to toxicity and monitoring in recipients of renal allografts. <i>Therapeutic Drug Monitoring</i> , 1997 , 19, 502-9	3.2	37
3	Analysis of methylated 6-mercaptopurine metabolites in human red blood cells: comparison of two methods. <i>Therapeutic Drug Monitoring</i> , 1997 , 19, 663-8	3.2	10
2	MONITORING OF AZATHIOPRINE TREATMENT BY DETERMINATION OF 6-THIOGUANINE NUCLEOTIDE CONCENTRATIONS IN ERYTHROCYTES ¹ . <i>Transplantation</i> , 1994 , 58, 803-807	1.8	20
1	Diastolic Time in Patients Treated with Timolol or Placebo after Acute Myocardial Infarction. <i>American Journal of Noninvasive Cardiology</i> , 1993 , 7, 220-224		